Therapeutic potential of cannabinoids in schizophrenia

Recent Patents on CNS Drug Discovery

Volumn 9, Issue 1, 2014, Pages 13-25

  Kucerova, Jana ^a   Tabiova, Katarina ^a   Drago, Filippo ^b   Micale, Vincenzo ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Animal models; Antipsychotics; Cannabidiol; Cannabis; CB receptors; Endocannabinoid system; Schizophrenia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AMPHETAMINE; CANNABICHROMENE; CANNABIDIOL; CANNABIGEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABIS; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRINABANT; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N OLEOYLETHANOLAMINE; NEUROTRANSMITTER; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VANILLOID RECEPTOR 1; CANNABINOID; CANNABINOID RECEPTOR AFFECTING AGENT; NEUROLEPTIC AGENT;

AMNESIA; ATTENTION DEFICIT DISORDER; CEREBELLUM; CEREBROSPINAL FLUID; CHEMICAL STRUCTURE; COGNITIVE DEFECT; HALLUCINATION; HIPPOCAMPUS; HUMAN; HUMAN CHROMOSOME; MATERNAL DEPRIVATION; MENTAL STRESS; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITIVE SYNDROME; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SENSORY GATING; SOCIAL BEHAVIOR; SOCIAL ISOLATION; SYMPTOMATOLOGY; ANIMAL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CANNABINOID RECEPTOR MODULATORS; CANNABINOIDS; HUMANS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84900552916     PISSN: 15748898     EISSN: 22123954     Source Type: Journal    
DOI: 10.2174/1574889809666140307115532     Document Type: Review

References (157)

1. American Psychiatric Association: Diagnostic and statistical manual of mental disorders (5th ed.). ed. A.P. Publishing 2013, Arlington, VA.
2. Kapur, S. What Kraepelin might say about schizophrenia: just the facts. Schizophr Res 2011; 128: 1-2.
3. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacol 2008; 33: 2061-79.
4. Micale V, Kucerova J, Sulcova, A. Leading compounds for the validation of animal models of psychopathology. Cell Tissue Res 2013; 354: 309-30.
5. Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 2012; 197: 1-6.
6. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31: 234-42.
7. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012; 17: 1206-27.
8. Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago, F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther 2013; 138: 18-37.
9. Micale V, Mazzola C, Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007; 56: 382-92.
10. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 2.
11. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134: 845-52.
12. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006; 103: 7895-900.
13. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, et al. Effects of cannabinoids and cannabinoidenriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011; 163:1479-94.
14. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037-43.
15. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 2010; 159: 129-41.
16. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol 2009; 51: 528-34.
17. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 2012; 133: 79-97.
18. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-27.
19. Costain WF. The effects of cannabis abuse on the symptoms of schizophrenia: patient perspectives. Int J Ment Health Nurs 2008; 17: 227-35.
20. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 2000; 34: 468-75.
21. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57:1117-27.
22. Bangalore SS, Prasad KMR, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr Res 2008; 99:1-6.
23. Ho BC, Wassink TH, Ziebell S, Andreasen NC. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 2011; 128: 66-75.
24. Rapp C, Walter A, Studerus E, Bugra H, Tamagni C, Röthlisberger M, et al. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Res 2013; 214: 102-8.
25. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry J Ment Sci 2007; 190: 230-6.
26. Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L, et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage 2013; 79: 304-12.
27. Dalton VS, Long LE, Weickert CS, Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacol 2011; 36: 1620-30.
28. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H] CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neurosci 2001; 103: 9-15.
29. Jenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM, et al. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr Res 2012; 141: 185-8.
30. Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006; 172: 556-60.
31. Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 355-60.
32. Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm Vienna Austria 1996 2007; 114: 1055-63.
33. Eggan SM, Stoyak SR, Verrico CD, Lewis DA. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder. Neuropsychopharmacol 2010; 35: 2060-71.
34. Eggan SM, Hashimoto T, Lewis DA. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 2008; 65: 772-84.
35. Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó V, et al. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacol (Berl) 2009; 206: 313-24.
36. Hamdani N, Tabeze J-P, Ramoz N, Ades J, Hamon M, Sarfati Y, et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2008; 18: 34-40.
37. Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S, Andreasen NC, et al. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med 2013; 43: 619-31.
38. Seifert J, Ossege S, Emrich HM, Schneider U, Stuhrmann, M. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 2007; 426: 29-33.
39. Stadelmann AM, Juckel G, Arning L, Gallinat J, Epplen JT, Roser P. Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neurosci Lett 2011; 496: 60-4.
40. Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2013; 38: 2568-77.
41. Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 2010; 67: 974-82.
42. Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS, Navarrete F, Manzanares, J. Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacol 2011; 36: 1489-504.
43. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2004; 29: 2108-14.
44. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665-9.
45. Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Meana JJ, Callado LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res 2013; 148: 145-50.
46. Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 2008; 29: 229-33.
47. Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, von Spulak F, Korte F. Effects of (--)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 1967; 11: 184-8.
48. Di Marzo V. Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. Pain 2012; 153: 1785-6.
49. Svizenska I, Dubovy P, Sulcova A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol Biochem Behav 2008; 90: 501-11.
50. Biro T, Toth BI, Hasko G, Paus R, Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci 2009; 30: 411-20.
51. Riebe CJ, Wotjak CT. Endocannabinoids and stress. Stress 2011; 14: 384-97.
52. Di Marzo V. "De-liver-ance" from CB(1): a way to counteract insulin resistance? Gastroenterol 2012; 142: 1063-6.
53. Di Marzo V, Piscitelli F. Gut feelings about the endocannabinoid system. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc 2011; 23: 391-8.
54. Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012; 33: 331-40.
55. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012; 12: 436-44.
56. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126: 21-38.
57. Silvestri C, Ligresti A, Di Marzo V. Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 2011; 12: 153-62.
58. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13: 420-3.
59. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
60. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
61. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Sci 1992; 258: 1946-9.
62. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
63. Lovinger DM. Endocannabinoid liberation from neurons in transsynaptic signaling. J Mol Neurosci 2007; 33: 87-93.
64. Marnett LJ. Decoding endocannabinoid signaling. Nat Chem Biol 2009; 5: 8-9.
65. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129-40.
66. Liu J, Wang L, Harvey-White J, Huang BX, Kim H-Y, Luquet S, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacol 2008; 54: 1-7.
67. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-7.
68. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 2002; 99: 10819-24.
69. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007; 114: 13-33.
70. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133-45.
71. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010; 17: 1360-81.
72. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci 2012; 367: 3216-28.
73. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 299-325.
74. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999; 11: 4213-25.
75. Haring M, Marsicano G, Lutz B, Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neurosci 2007; 146: 1212-9.
76. Oropeza VC, Mackie K, Van Bockstaele EJ. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 2007; 1127: 36-44.
77. Gong J-P, Onaivi ES, Ishiguro H, Liu Q-R, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10-23.
78. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Sci 2005; 310: 329-32.
79. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions throughout lifespan: a discussion on therapeutic perspectives. J Psychopharmacol 2012; 26: 150-63.
80. Jones CA, Watson DJ, Fone KC. Animal models of schizophrenia. Br J Pharmacol 2011; 164: 1162-94.
81. Murray RM, Lappin J, Di Forti M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur Neuropsychopharmacol 2008; 18 Suppl 3: S129-34.
82. Pratt J, Winchester C, Dawson N, Morris B. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 2012; 11: 560-79.
83. Peleg-Raibstein D, Feldon J, Meyer U. Behavioral animal models of antipsychotic drug actions. Handb Exp Pharmacol 2012; 361-406.
84. Mouri A, Nagai T, Ibi D, Yamada K. Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Neurobiol Dis 2013; 53: 61-74.
85. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-55.
86. Spano MS, Fattore L, Cadeddu F, Fratta W, Fadda P. Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacol (Berl) 2013; 225: 531-42.
87. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, et al. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacol 2008; 54: 815-23.
88. Przegalinski E, Gothert M, Frankowska M, Filip M. WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. Eur J Pharmacol 2005; 517: 68-73.
89. Long LE, Chesworth R, Huang X-F, McGregor IS, Arnold JC, Karl T. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP 2010; 13: 861-76.
90. Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 2009; 93: 91-6.
91. Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005; 512: 199-205.
92. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacol (Berl) 1991; 104: 260-4.
93. Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, et al. Effects of cannabidiol on amphetamineinduced oxidative stress generation in an animal model of mania. J Psychopharmacol Oxf Engl 2011; 25: 274-80.
94. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94.
95. Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological wellbeing. Psychol Med 2012; 42: 391-400.
96. Robson, PJ, Guy, GW, and Di Marzo, V. Cannabinoids and Schizophrenia: Therapeutic Prospects. Curr Pharm Des 2013; in press.
97. Zuardi AW, Crippa JAS, Hallak JEC, Bhattacharyya S, Atakan Z, Martin-Santos R, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 2012; 18: 5131-40.
98. Guy, G., Kikuchi, T., Maeda, K., Robson, P., Stott, C. Use of cannabinoids in combination with an anti-psychotic medicament. WO200908735A1(2009).
99. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
100. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
101. Poncelet M, Barnouin MC, Breliere JC, Le Fur G, Soubrie P. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacol (Berl) 1999; 144: 144-50.
102. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138: 544-53.
103. Madsen MV, Peacock L, Werge T, Andersen MB. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. J Psychopharmacol 2006; 20: 622-8.
104. Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, et al. Effects of cannabinoid receptor ligands on psychosisrelevant behavior models in the rat. Psychopharmacol (Berl) 2003; 165: 128-35.
105. Miller DK, Rodvelt KR, Constales C, Putnam WC. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamineinduced hyperactivity. Life Sci 2007; 81: 63-71.
106. Ferrer B, Gorriti MA, Palomino A, Gornemann I, de Diego Y, Bermudez-Silva FJ, et al. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. Eur J Pharmacol 2007; 559: 180-3.
107. Black MD, Stevens RJ, Rogacki N, Featherstone RE, Senyah Y, Giardino O, et al. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychoticside effects in rodents. Psychopharmacol (Berl) 2011; 215: 149-63.
108. Anavi-Goffer, S., Gertsch, J. Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists. WO2013140342A1 (2013).
109. Seillier A, Martinez AA, Giuffrida A. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB(1) receptors: implications for schizophrenia. Neuropsychopharmacol 2013; 38: 1816-24.
110. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCPtreated rats. Int J Neuropsychopharmacol 2010; 13: 373-86.
111. Compton MT, Weiss PS, West JC, Kaslow NJ. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol 2005; 40: 939-46.
112. Dubertret C, Bidard I, Ades J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res 2006; 86: 284-90.
113. Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry 2009; 21: 152-62.
114. Zamberletti E, Piscitelli F, Cadeddu F, Rubino T, Fratta W, Fadda P, et al. Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. Br J Pharmacol 2012; 167: 1652-64.
115. Guidali C, Viganò D, Petrosino S, Zamberletti E, Realini N, Binelli G, et al. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP 2011; 14: 17-28.
116. Haller J, Szirmai M, Varga B, Ledent C, Freund TF. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol 2005; 16: 415-22.
117. Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2011; 31: 86-91.
118. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004; 161: 975-84.
119. Bellocchio, L., Cota, D., Felpin, F.X., Maldonado, R., Marsicano, G., Piazza, P.V., Revest, J.M., Spampinato, U., Vallee, M., Vitiello, S. Antagonists of cb1 receptor. WO2012160006A1 (2012).
120. Black, M., Borowsky, B., Rogacki, N., Senyah, Y., Stevens, R. Use of a cb1 antagonist for treating negative symptoms of schizophrenia. WO2007067617A3 (2007).
121. Celly, C.S., Demond, D.E., Gilbert, E.J., Greenlee, W.J., Miller, M.W., Scott, J.D., Stamford, A. Substituted piperazines as cb1 antagonists. WO2009005646A3 (2009).
122. Kruse, C.G., Lange, J.H.M. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition. WO2008084057A1 (2008).
123. Lazzari, P., Loriga, G., Manca, I., Pinna, G.A. Tricyclic condensed pyrazole derivatives as CB1 inhibitors. EP2223914A1 (2010).
124. Lichtman AH, Martin BR. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacol (Berl) 1996; 126: 125-31.
125. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacol (Berl) 2006; 188: 425-44.
126. Vigano D, Guidali C, Petrosino S, Realini N, Rubino T, Di Marzo V, et al. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP 2009; 12: 599-614.
127. Hampson RE, Deadwyler SA. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 2000; 20: 8932-42.
128. Mallet PE, Beninger RJ. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. Psychopharmacol (Berl) 1998; 140: 11-9.
129. Zamberletti E, Vigano D, Guidali C, Rubino T, Parolaro D. Longlasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol 2012; 15: 267-80.
130. Zamberletti E, Rubino T, Parolaro D. The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des 2012; 18: 4980-90.
131. Roser P, Haussleiter IS, Chong H-J, Maier C, Kawohl W, Norra C, et al. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacol (Berl) 2011; 218: 611-20.
132. Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J, et al. Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 2012; 134: 207-10.
133. Hu, J. 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands. US8426448B2 (2013).
134. Schaus, JM. 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands. WO2009131815A1 (2009).
135. Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci 2011; 32: 270-80.
136. Greig, I.R., Pertwee, R.G., Ross, R.A. 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents. WO2008099139A1 (2008).
137. Makriyannis, A., Vemuri, V.K. CB1 receptor antagonists and uses thereof. US20130123229A1 (2013).
138. Wright MJ, Vandewater SA, Taffe MA. Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol. Br J Pharmacol 2013; 170: 1365-73.
139. Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol Oxf Engl 2013; 27: 19-27.
140. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1071-9.
141. Bortolato M, Aru GN, Frau R, Orrù M, Luckey GC, Boi G, et al. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacol (Berl) 2005; 177: 264-71.
142. Schneider M, Drews E, Koch M. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2. Behav Pharmacol 2005; 16: 447-54.
143. Brzozka MM, Fischer A, Falkai P, Havemann-Reinecke U. Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice. Behav Brain Res 2011; 218: 280-7.
144. Malone DT, Taylor DA. The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav Brain Res 2006; 166: 101-9.
145. Spano MS, Fadda P, Frau R, Fattore L, Fratta W. Cannabinoid selfadministration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol 2010; 20: 25-36.
146. Fernandez-Espejo E, Galan-Rodriguez B. Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor. Psychopharmacol (Berl) 2004; 175: 220-4.
147. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2006; 31: 2652-9.
148. Geyer MA, Swerdlow NR. Measurement of startle response, prepulse inhibition, and habituation. Curr Protoc Neurosci 2001; Chapter 8: Unit 8.7.
149. Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, et al. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 2007; 32: 2098-107.
150. Malone DT, Long LE, Taylor DA. The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol Biochem Behav 2004; 77: 839-45.
151. Fitzgerald PB, Daskalakis ZJ. Concurrent treatment of depression and auditory hallucinations in a patient with schizophrenia. Aust N Z J Psychiatry 2011; 45: 681-3.
152. Marongiu MF, Poddie D, Porcu S, Manchinu MF, Castelli MP, Sogos V, et al. Reversible disruption of pre-pulse inhibition in hypomorphic-inducible and reversible CB1-/-mice. PloS One 2012; 7: e35013.
153. Long LE, Chesworth R, Huang X-F, Wong A, Spiro A, McGregor IS, et al. Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PloS One 2012; 7: e34129.
154. Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacol 2006; 31: 795-803.
155. Desbonnet L, O'Tuathaigh CM, Waddington JL. Modeling schizophrenia: uncovering novel therapeutic targets. Expert Rev Clin Pharmacol 2012; 5: 667-76.
156. Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G, et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci Off J Soc Neurosci 2000; 20: 3401-7.
157. Zamberletti E, Prini P, Speziali S, Gabaglio M, Solinas M, Parolaro D, et al. Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neurosci 2012; 204: 245-57.